Mary Ann McLaughlin

From Wikipedia, the free encyclopedia
Mary Ann McLaughlin
Born1968 (age 52–53)
Alma mater
Scientific career
FieldsCardiologist
InstitutionsMount Sinai Medical Center

Mary Ann McLaughlin (born 1968) is an American cardiologist, the author of multiple book chapters and an associate professor at Mount Sinai Medical Center in New York City.

Her research – funded with grants from the Agency for Healthcare Research and Quality, the National Institutes of Health, the American Heart Association, the American College of Cardiology and the New York Academy of Medicine – focuses on the improvement of cardiovascular care for women, the elderly and minorities.[1]

Biography[]

McLaughlin received her B.A. in Biology from the University of Virginia in 1984 and graduated from Georgetown University School of Medicine in 1990 as member of the Alpha Omega Alpha Medical Honor Society.[2][failed verification] She completed both an internship and residency at NewYork-Presbyterian Hospital in 1993 and received her Master's in Public Health from Columbia University School of Public Health in 1996.

She is co-founder of the Women's Cardiac Assessment and Risk Evaluation Program at the Mount Sinai Medical Center, serves on the editorial board of Focus on Healthy Aging and, as of July 2008, is a member of the American Heart Association's Boards of Directors (East Coast region).[3]

Awards and honors[]

  • American College of Cardiology/Merck Fellowship Award
  • C. Richard Bowman Award (awarded to the New York Hospital house officer demonstrating human warmth, scientific endeavor, and dedication to medicine)
  • Mary and David Hoar Fellowship of the New York Academy of Medicine[4][failed verification]
  • SmithKline Beecham Development Partners Junior Faculty Award in Cardiology
  • Arthur Ross Foundation Award
  • B. Chaus Scholar Cardiology Award, Mount Sinai Medical Center

Memberships[]

  • President, American Heart Association, NYC Board
  • American Heart Association, Board of Directors, Northeast Region July 2008 – present
  • American Heart Association, Member 1997–present
  • American Heart Association, Invited National Spokesperson 2004-2005
  • Mount Sinai Cardiovascular Institute Compliance Committee January 2007 – present
  • Mount Sinai School of Medicine Alumni Association Executive Committee, January 2007 – present
  • National Institutes of Health, National Center on Minority Health and Health Disparities, Grant Review Committee, June 2005
  • Women with Heart, Executive Committee 2004–present
  • American College of Cardiology, Fellow, inducted 1999
  • Editorial Board, Focus on Healthy Aging, A Belvoir Publications, Mahopac, NY. 2002–present
  • Mount Sinai School of Medicine Re-Engineering Electronic Medical Records Committee, 1998-1999
  • Mount Sinai School of Medicine Quality Assurance Subcommittee 1999
  • Mount Sinai School of Medicine Cardiothoracic Chair Search Committee, 1999-2000

Publications[]

Partial list:

  • Mennell JS, Cesarman GM, Jacovina AT, Mclaughlin M, Lev EA, Hajjar KA. Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 1991; 340: 994-1004.
  • Mclaughlin M, Fuster V. Three mechanisms for coronary artery disease progression; insights into future management. Mount Sinai Journal of Medicine 1995; 62(4): 265-274.
  • Mclaughlin M, Phillips RA, Patel TN, Siu AL, David O, Buckley S, Mara T, Goldman ME. Prevalence and treatment patterns of diastolic filling abnormalities in the elderly. Journal of Heart Failure 1997; 4(1): 110.
  • Gersony DR, Mclaughlin M, Sacks HS, Fuster V, Gersony WM. Effect of beta blocker therapy on clinical outcome in patients with Marfans syndrome: Meta-analysis of data from 802 patients. JACC 1999; 33(2): 243.
  • Lala A, McLaughlin MA. Do all ACE inhibitors provide the same outcomes benefits in high-risk cardiovascular patients? Curr Hypertens Rep. 2008Aug;10(4):286-92. PMID 18625157
  • Choi BG, McLaughlin MA. Why men’s hearts break: cardiovascular effects of sex steroids. Endocrinol Metab Clin North Am. 2007 June;36(2):365-77. PMID 17543724
  • Khan RA, Moskowitz DM, Marin ML, Hollier LH, Parsons R, Teodorescu V, McLaughlin MA, Safety and Efficacy of High Dose Adenosine–induced A Systole During Endovascular AAA Repair. J Endovasc Ther 2000; 7:292-296.
  • Hebert, PL, Sisk JE, Wang, J, Horowitz, CR, Chassin MR, McLaughlin, MA. Cost-effectiveness of nurse-led disease management for heart failure in a racially diverse urban community. Annals of Internal Medicine, Accepted for publication 8/13/08.

References[]

  1. ^ Niss, Barbara; Aufses, Arthur H. (2005). Teaching Tomorrow's Medicine Today: The Mount Sinai School of Medicine, 1963-2003. NYU Press. p. 234. ISBN 978-0-8147-0706-7.
  2. ^ "Combining Lab Tests Helps Identify Heart Risks". University of Virginia Health System. September 2005. Archived from the original on 2006-02-12.
  3. ^ American College of Cardiology[permanent dead link]
  4. ^ Hannan, Edward L.; Magaziner, Jay; Wang, Jason J.; Eastwood, Elizabeth A.; Silberzweig, Stacey B.; Gilbert, Marvin; Morrison, R. Sean; McLaughlin, Mary Ann; Orosz, Gretchen M.; Siu, Albert L. (2001-06-06). "Mortality and Locomotion 6 Months After Hospitalization for Hip Fracture". JAMA. 285 (21): 2736. doi:10.1001/jama.285.21.2736. ISSN 0098-7484.
Retrieved from ""